Disc Medicine (IRON) CLO Rahul Khara Sells $124K of Stock
Rahul Khara, Chief Legal Officer at Disc Medicine, sold 1,649 shares on June 29, 2026, valued at $123,675.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rahul Khara, Chief Legal Officer at Disc Medicine, Inc. ($IRON), sold 1,649 shares at an average price of $75, worth about $123,675, on June 29, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $IRON is up 3.4% after 1 week, down 1.1% after 1 month and down 23.7% to date (from the $74.50 close on Jun 29, 2026).
IRON
Disc Medicine, Inc.
Key Points
- Rahul Khara sold 1,649 shares of Disc Medicine, Inc. for about $123,675 on June 29, 2026.
- This sale follows Khara's recent purchases of 8,351 shares combined on June 18 and June 26, showing his continued investment in the company.
- Disc Medicine currently has a mean analyst target price of $103.17, with most analysts rating it as a strong buy.
Get $IRON trade alerts by text
We text you when insiders, Congress or big funds trade $IRON. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Disc Medicine, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Disc Medicine, Inc.
Rahul Khara, the Chief Legal Officer of Disc Medicine, Inc. (NasdaqGM: IRON), sold 1,649 shares on June 29, 2026, at a price of $75.00 per share. This sale totaled approximately $123,675. The transaction was planned and reflects Khara's continued management of his investment strategy regarding the company's stock.
Recent Insider Activity
This sale comes shortly after Khara purchased 851 shares on June 26 for around $12,501, and 7,500 shares on June 18 valued at about $110,175. His recent buying activity indicates a belief in the company's prospects, despite the decision to sell some shares now. Other insiders, including Yu Jonathan Yen-Wen, the COO, sold 9,700 shares on June 22, which adds to a wave of insider trading at Disc Medicine in recent weeks.
Analysts Set New Price Targets
Analysts continue to show confidence in Disc Medicine's future. On September 16, 2026, Wells Fargo maintained an Overweight rating with a target price of $86.00. Wedbush has reiterated an Outperform rating with a price target of $100.00 on September 10, and HC Wainwright & Co. maintained a Buy rating, raising their target to $120.00 on August 6. The consensus among 12 analysts is a strong buy with a mean target price of $103.17.
Stock Overview
Currently, Disc Medicine's shares are trading at $73.14, which is closer to its 52-week low of $40.00 than to its high of $99.50. The stock trades below its 50-day moving average of $76.60, suggesting it may be undervalued compared to its recent performance. Investors may be watching for the next earnings report scheduled for November 5, 2026, to gauge the company’s financial health and market position.
About Disc Medicine, Inc.
Disc Medicine, Inc. focuses on developing innovative treatments for serious blood-related diseases. Their work involves understanding and modifying biological pathways that affect red blood cell function. This strategic selling and buying by insiders reflect ongoing confidence in their pipeline and the company's overall potential.
What’s Next for Disc Medicine
With the next earnings date set for November 5, 2026, investors may look for insights into the company's performance and progress in its drug development pipeline. As always, keep in mind that this insider activity reflects past trading behaviors, and the upcoming reports will be crucial in assessing Disc Medicine's future trajectory.
Related Filing Alerts
Source: Rahul Khara's Form 4 filing on $IRON (Jun 29, 2026). Find the original filing: IRON Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts